Biogen Inc BIIB
News
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Biogen Reports Progress on Corporate Responsibility Priorities
Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
'Patients got better faster': Music therapy provides new hope after strokes.
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors